Inserm, UMR991, Liver Metabolisms and Cancer, Rennes, France; Université de Rennes 1, Rennes, France; CHU Rennes, Service de Chirurgie Hépatobiliaire et Digestive, Rennes, France.
Hepatology. 2013 Dec;58(6):1992-2000. doi: 10.1002/hep.26577. Epub 2013 Oct 17.
Intrahepatic cholangiocarcinoma (ICC) is the second most common type of primary cancer in the liver. ICC is an aggressive cancer with poor prognosis and limited therapeutic strategies. The identification of new drug targets and prognostic biomarkers is an important clinical challenge for ICC. The presence of an abundant stroma is a histological hallmark of ICC. Given the well-established role of the stromal compartment in the progression of cancer diseases, we hypothesized that relevant biomarkers could be identified by analyzing the stroma of ICC. By combining laser capture microdissection and gene expression profiling, we demonstrate that ICC stromal cells exhibit dramatic genomic changes. We identified a signature of 1,073 nonredundant genes that significantly discriminate the tumor stroma from nontumor fibrous tissue. Functional analysis of differentially expressed genes demonstrated that up-regulated genes in the stroma of ICC were related to cell cycle, extracellular matrix, and transforming growth factor beta (TGFβ) pathways. Tissue microarray analysis using an independent cohort of 40 ICC patients validated at a protein level the increased expression of collagen 4A1/COL4A1, laminin gamma 2/LAMC2, osteopontin/SPP1, KIAA0101, and TGFβ2 genes in the stroma of ICC. Statistical analysis of clinical and pathological features demonstrated that the expression of osteopontin, TGFβ2, and laminin in the stroma of ICC was significantly correlated with overall patient survival. More important, multivariate analysis demonstrated that the stromal expression of osteopontin was an independent prognostic marker for overall and disease-free survival.
The study identifies clinically relevant genomic alterations in the stroma of ICC, including candidate biomarkers for prognosis, supporting the idea that tumor stroma is an important factor for ICC onset and progression.
肝内胆管细胞癌(ICC)是肝脏的第二大常见原发性癌症。ICC 是一种侵袭性癌症,预后不良,治疗策略有限。鉴定新的药物靶点和预后生物标志物是 ICC 的重要临床挑战。丰富的基质存在是 ICC 的组织学特征。鉴于基质在癌症疾病进展中的作用已得到充分确立,我们假设通过分析 ICC 的基质可以鉴定出相关的生物标志物。通过结合激光捕获显微解剖和基因表达谱分析,我们证明了 ICC 基质细胞表现出明显的基因组变化。我们确定了一个由 1073 个非冗余基因组成的特征,这些基因可显著区分肿瘤基质与非肿瘤纤维组织。差异表达基因的功能分析表明,ICC 基质中上调的基因与细胞周期、细胞外基质和转化生长因子β(TGFβ)途径有关。使用 40 名 ICC 患者的独立队列进行组织微阵列分析,在蛋白质水平验证了胶原蛋白 4A1/COL4A1、层粘连蛋白γ 2/LAMC2、骨桥蛋白/SPP1、KIAA0101 和 TGFβ2 基因在 ICC 基质中的表达增加。对临床和病理特征的统计分析表明,ICC 基质中骨桥蛋白、TGFβ2 和层粘连蛋白的表达与患者总生存显著相关。更重要的是,多变量分析表明,骨桥蛋白在 ICC 基质中的表达是总生存和无病生存的独立预后标志物。
该研究确定了 ICC 基质中具有临床意义的基因组改变,包括用于预后的候选生物标志物,支持肿瘤基质是 ICC 发生和进展的重要因素的观点。